BioLight enters into agreement to distribute ophthalmology laser in Asia
BioLight Life Sciences Investments has signed an exclusive distribution agreement for sales and marketing of IOPtima's IOPtiMate ophthalmology laser system in Hong Kong and Macao.
BioLight Life Sciences Investments (Tel Aviv, Israel), a firm that invests in, manages, and commercializes ophthalmology and cancer diagnostics innovations, has signed an exclusive distribution agreement for sales and marketing of IOPtima's (also in Tel Aviv) IOPtiMate ophthalmology laser system in Hong Kong and Macao. The initial term of the agreement includes the purchase of at least nine systems.
Related: IOptima receives European patent approval for laser system for treatment of glaucoma
The system, based on CO2 laser technology, enables a unique filtration surgery to treat glaucoma without penetrating the inner part of the eyeball, allowing for substantial reductions in post-operative complications and use of eye drops compared with alternatives.
A medical center in Hong Kong recently purchased the system, while an additional system has been installed on a trial basis at a second Hong Kong-based medical center.
The company began marketing to physicians and medical centers in China after receiving approval in March 2014 from the China Food and Drug Administration (CFDA) to market and sell the system.
(Thumbnail image via Shutterstock)
Follow us on Twitter, 'like' us on Facebook, connect with us on Google+, and join our group on LinkedIn
Subscribe now to BioOptics World magazine; it's free!